Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone

PURPOSE OF REVIEW: The widespread respiratory disease of virus known as severe acute respiratory syndrome–coronavirus 2019 (SAR-CoV-2) had infected more than 200 countries and caused pandemic and havoc in the world. RECENT FINDINGS: The genome of the virus was sequenced rapidly to study its mechanis...

Descripción completa

Detalles Bibliográficos
Autores principales: Sood, Shivani, Bhatia, Gurpreet Kaur, Seth, Prachi, Kumar, Pawan, Kaur, Jagjit, Gupta, Vidisha, Punia, Sandeep, Tuli, Hardeep Singh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Clinical Pharmacology (L Brunetti, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889701/
https://www.ncbi.nlm.nih.gov/pubmed/33619447
http://dx.doi.org/10.1007/s40495-021-00253-w
_version_ 1783652363820597248
author Sood, Shivani
Bhatia, Gurpreet Kaur
Seth, Prachi
Kumar, Pawan
Kaur, Jagjit
Gupta, Vidisha
Punia, Sandeep
Tuli, Hardeep Singh
author_facet Sood, Shivani
Bhatia, Gurpreet Kaur
Seth, Prachi
Kumar, Pawan
Kaur, Jagjit
Gupta, Vidisha
Punia, Sandeep
Tuli, Hardeep Singh
author_sort Sood, Shivani
collection PubMed
description PURPOSE OF REVIEW: The widespread respiratory disease of virus known as severe acute respiratory syndrome–coronavirus 2019 (SAR-CoV-2) had infected more than 200 countries and caused pandemic and havoc in the world. RECENT FINDINGS: The genome of the virus was sequenced rapidly to study its mechanism, epidemiology, drugs, and vaccines. Many drugs and vaccines are being studied by researchers to treat and prevent the SARS-CoV-2. Favipiravir and dexamethasone are repurposed drugs which showed therapeutic potential and pharmaceutical efficacy against SARS-CoV-2. SUMMARY: The review describes the path of favipiravir and dexamethasone from chemistry to mechanisms of action to combat SARS-CoV-2. In addition, the potential side effects are also summarized to study their potential to control corona virus 2019.
format Online
Article
Text
id pubmed-7889701
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-78897012021-02-18 Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone Sood, Shivani Bhatia, Gurpreet Kaur Seth, Prachi Kumar, Pawan Kaur, Jagjit Gupta, Vidisha Punia, Sandeep Tuli, Hardeep Singh Curr Pharmacol Rep Clinical Pharmacology (L Brunetti, Section Editor) PURPOSE OF REVIEW: The widespread respiratory disease of virus known as severe acute respiratory syndrome–coronavirus 2019 (SAR-CoV-2) had infected more than 200 countries and caused pandemic and havoc in the world. RECENT FINDINGS: The genome of the virus was sequenced rapidly to study its mechanism, epidemiology, drugs, and vaccines. Many drugs and vaccines are being studied by researchers to treat and prevent the SARS-CoV-2. Favipiravir and dexamethasone are repurposed drugs which showed therapeutic potential and pharmaceutical efficacy against SARS-CoV-2. SUMMARY: The review describes the path of favipiravir and dexamethasone from chemistry to mechanisms of action to combat SARS-CoV-2. In addition, the potential side effects are also summarized to study their potential to control corona virus 2019. Springer International Publishing 2021-02-18 2021 /pmc/articles/PMC7889701/ /pubmed/33619447 http://dx.doi.org/10.1007/s40495-021-00253-w Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Clinical Pharmacology (L Brunetti, Section Editor)
Sood, Shivani
Bhatia, Gurpreet Kaur
Seth, Prachi
Kumar, Pawan
Kaur, Jagjit
Gupta, Vidisha
Punia, Sandeep
Tuli, Hardeep Singh
Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone
title Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone
title_full Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone
title_fullStr Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone
title_full_unstemmed Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone
title_short Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone
title_sort efficacy and safety of new and emerging drugs for covid-19: favipiravir and dexamethasone
topic Clinical Pharmacology (L Brunetti, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889701/
https://www.ncbi.nlm.nih.gov/pubmed/33619447
http://dx.doi.org/10.1007/s40495-021-00253-w
work_keys_str_mv AT soodshivani efficacyandsafetyofnewandemergingdrugsforcovid19favipiraviranddexamethasone
AT bhatiagurpreetkaur efficacyandsafetyofnewandemergingdrugsforcovid19favipiraviranddexamethasone
AT sethprachi efficacyandsafetyofnewandemergingdrugsforcovid19favipiraviranddexamethasone
AT kumarpawan efficacyandsafetyofnewandemergingdrugsforcovid19favipiraviranddexamethasone
AT kaurjagjit efficacyandsafetyofnewandemergingdrugsforcovid19favipiraviranddexamethasone
AT guptavidisha efficacyandsafetyofnewandemergingdrugsforcovid19favipiraviranddexamethasone
AT puniasandeep efficacyandsafetyofnewandemergingdrugsforcovid19favipiraviranddexamethasone
AT tulihardeepsingh efficacyandsafetyofnewandemergingdrugsforcovid19favipiraviranddexamethasone

Ejemplares similares